• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

The "Sweet Spot" in Type 2 Diabetes Management

News
Slideshow

The new "sweet spot" in diabetes management is the interdisciplinary approach that is essential to treating all aspects of the disease. New diabetes medications also hit that spot.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
First Rivaroxaban Generics (2.5 mg) Get FDA Approval / image credit ©samunella/stock.adobe.com

First Rivaroxaban Generics (2.5 mg) Get FDA Approval

Grace Halsey
March 5th 2025
Article

The first low-dose rivaroxaban generic tablets to be FDA approved lead a field crowded with applications for formulations of all the higher doses.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

FDA Clears Google Pixel Watch 3 Loss of Pulse Detection Feature

FDA Clears Google Pixel Watch 3 Loss of Pulse Detection Feature

Sydney Jennings
February 28th 2025
Article

The Loss of Pulse Detection feature will begin rolling out in the US late next month.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Diabetes

FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Diabetes

Patient Care Editorial Staff
February 14th 2025
Article

Merilog joins two long-acting insulin biosimilar products approved in 2021, bringing the total to three insulin biosimilars available in the United States.

Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose / image credit: ©New Africa/AdobeStock

Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose

Sydney Jennings
February 13th 2025
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.